12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Actemra regulatory update

Roche disclosed in its 4Q10 earnings that last year it submitted regulatory applications in the U.S. and EU to expand the label of tocilizumab to include the treatment of systemic juvenile idiopathic arthritis. The humanized mAb against IL-6 is approved for adult rheumatoid arthritis in Australia, Brazil, India, Japan and Switzerland, as well as the EU, where it is called RoActemra. The product is approved in the U.S. as Actemra to treat moderate to severe RA and for the...

Read the full 375 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >